Highlights from EHA 2017:
2 CML experts give their personal perspectives

Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia

• Phase II study on dasatinib in children and adolescents with CML-CP
• 10-year survival results of the German CML IV Study
• Year 2 results from the British Destiny Study 
• Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
• Update on treatment-free remission studies

 {rscomments off}